Wockhardt shares hit an all-time high of ₹2,420 on the BSE on Monday, surging 19% in intra-day trade following the company's announcement of securing US FDA approval for its novel antibiotic drug named Zaynich. According to Outlook Business, the stock was trading 11.42% higher at ₹2,262.65 by 11:13 AM, with around 2.7 million equity shares changing hands across NSE and BSE in the first 11 minutes of trading. The shares have demonstrated exceptional momentum with a 64% gain over the past month, significantly outperforming the 3% decline in the BSE Sensex during the same period. This represents a substantial upgrade from the previous 60% gain over the past month reported by Upstox Securities, reflecting continued positive investor sentiment around the regulatory milestone.
The Zaynich antibiotic is specifically designed to address 2.8 million antimicrobial-resistant infection cases that occur annually in the United States, with over 35,000 deaths each year according to company data. The drug targets complicated urinary tract infections, which account for more than 600,000 hospitalizations annually in the US, with a growing proportion linked to antimicrobial-resistant and multidrug-resistant bacteria. As per Outlook Business, the drug's estimated market opportunity in the US alone is $9 billion, representing a significant market opportunity as the drug addresses a critical healthcare need in the American market. The drug is approved for treating complicated urinary tract infections (cUTI), including pyelonephritis, in adults, positioning it directly against this substantial market segment. However, commercialising novel antibiotics has historically been difficult despite the urgent medical need, with newer drugs typically reserved for the most severe cases to avoid overuse and preserve effectiveness.
The US FDA approval represents a crucial regulatory achievement for Wockhardt, enabling the company to commercialize its antibiotic drug in the American market. The approval was based on results from the Phase 3 ENHANCE-1 study, a randomized, double-blind, multicentre trial that evaluated ZAYNICH against meropenem in hospitalized adults. In the study, ZAYNICH achieved a composite clinical cure and microbiological response rate of 89% at the test-of-cure visit, compared with 68.4% for meropenem, with a treatment difference of 20.6% and 95% confidence interval of 12.3 to 29.5. The drug had earlier received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA. According to Outlook Business, the company expects US market exclusivity for Zaynich to extend to approximately 2038, providing substantial protection for its investment in this novel antibiotic. The company also received Central Drugs Standard Control Organisation (CDSCO) authorization on May 28 for import and marketing of the same drug in India. This approval marks a significant milestone as Zaynich becomes the first New Chemical Entity (NCE) discovered and developed in India to receive US FDA clearance, highlighting the rarity of successful drug discovery programmes emerging from the country's pharmaceutical sector.
The Zaynich antibiotic combines cefepime and zidebactam as a novel intravenous formulation for complicated urinary tract infections. According to Outlook Business, the drug operates through a "beta-lactam enhancer mechanism" that simultaneously blocks two sequential steps in a bacterial pathway, enabling it to act against superbugs resistant to existing antibiotic treatments. As Huzefa Patel, Chief Mentor for Drug Discovery at Wockhardt, told the Economic Times, "The synergy generated is so powerful that it overcomes virtually all known resistance mechanisms." The company has also submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency and received approval from the Drugs Controller General of India (DCGI) on May 27, 2026. The ENHANCE-1 study enrolled 530 patients across 64 sites spanning the United States, Europe, Latin America, China and India. Prior to the Phase 3 program, Zaynich was evaluated across nine Phase 1 studies and a Phase 2 clinical study involving patients with documented meropenem-resistant Gram-negative infections, with the Phase 2 study conducted across 15 leading tertiary care hospitals in India demonstrating over 97% clinical efficacy across serious infections including hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, bloodstream infections, complicated intra-abdominal infections, and cUTI.
Wockhardt's financial performance has shown significant improvement, with the company reporting revenue growth of 12.9% in FY2026, driven by expansion in its biosimilars business in emerging markets and continued growth in Europe and India. According to Outlook Business, operating profit margin improved to 19.2% in FY2026 from 13.1% in FY2025, attributed to greater focus on margin-accretive segments, cost rationalisation measures, and exit from the loss-making US generics business. On May 21, ICRA upgraded the credit ratings on Wockhardt's long-term and short-term bank facilities, citing improved financial performance, healthy market position in India and Europe, adequate liquidity, and stronger capital structure. The company currently has six antibiotics at various stages of clinical development and commercialisation, with three targeting Gram-Negative pathogens and three targeting Gram-Positive infections, all having received Qualified Infectious Disease Product (QIDP) designation from the US FDA. Latest financial data shows revenue rose to ₹3,373 crore in FY26 from ₹2,651 crore in FY23, while EBITDA margins expanded from 4% to 19% during the same period, with the company returning to profitability during this period.
